本页面由Tiger Trade Technology Pte. Ltd.提供服务

Seres Therapeutics, Inc.

9.33
+0.19002.08%
成交量:2.28万
成交额:21.12万
市值:8,944.02万
市盈率:14.58
高:9.49
开:9.00
低:9.00
收:9.14
52周最高:29.98
52周最低:6.53
股本:958.63万
流通股本:729.26万
量比:0.42
换手率:0.31%
股息:- -
股息率:- -
每股收益(TTM):0.6400
每股收益(LYR):0.0175
净资产收益率:19.64%
总资产收益率:-42.25%
市净率:2.02
市盈率(LYR):533.05

数据加载中...

公司资料

公司名字:
Seres Therapeutics, Inc.
交易所:
NASDAQ
成立时间:
2010
员工人数:
66
公司地址:
101 Cambridgepark Drive,Cambridge,Massachusetts,United States
邮编:
02140
电话:
传真:
- -
简介:
Seres Therapeutics, Inc.于2010年10月根据特拉华州法律注册成立。该公司是一家临床阶段的生物制药公司,专注于为医疗脆弱人群开发活体生物治疗产品。其研发管线针对感染及炎症和免疫疾病,并利用首个获得FDA批准的口服微生物组疗法VOWST的开发经验所建立的平台。

董事

名称
职位
Richard N. Kender
Director and Executive Chair and Interim Chief Executive Officer
Claire M. Fraser
Director
Dennis A. Ausiello
Director
Eric D. Shaff
Director
Hans Juergen Woerle
Director
Kurt C. Graves
Director
Robert Rosiello
Director
Stephen Berenson
Director
Willard H. Dere
Director

股东

名称
职位
Richard N. Kender
Director and Executive Chair and Interim Chief Executive Officer
Kelly Brady
Chief Operating Officer and Executive Vice President
Marella Thorell
Chief Financial Officer and Executive Vice President
Matthew Henn
Chief Scientific Officer and President
Teresa L. Young
Chief Commercial and Strategy Officer and Executive Vice President
Thomas J. DesRosier
Chief Legal Officer and Executive Vice President